Combination treatment using the COX-2 inhibitor meloxicam and an anti-allergic in pollinosis

Journal of International Medical Research

Volumn 32, Issue 6, 2004, Pages 655-664

  Takechi, M ^a  

^a Tsuchibashi Shinryosho Clinic   (Japan)

Author keywords

Anti allergic; Chronic inflammation; COX 2; Epinastine; Meloxicam; Pollinosis

Indexed keywords

ANTIALLERGIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; EPINASTINE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PRANOPROFEN; PREDNISOLONE; PREDONIN; STEROID;

ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; FEMALE; HUMAN; MALE; MONOTHERAPY; OPEN STUDY; POLLEN ALLERGY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 9444269222     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000403200611     Document Type: Article

References (14)

1. Limmroth V, Katsarava Z, Diener HC: Acetylsalicylic acid in the treatment of headache. Cephalalgia 1999; 19: 545-551.
2. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235.
3. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991; 88: 2692-2696.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-12872.
5. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR: Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992; 267: 4338-4344.
6. Pairet M, van Ryn J: Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998; 47 (Suppl 2): S93-S101.
7. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105-110.
8. Wallace IL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK: Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998; 115: 101-109.
9. Oka M, Inaba A, Uchiyama T, Hazama S, Shimoda K, Suzuki M, et al: Prostaglandin E2 levels and lymphocyte subsets in portal venous drainage of colorectal cancers. Am J Surg 1994; 167: 264-267.
10. 2. Gut 1994; 35: 675-678.
11. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
12. Dobbie Z, Muller PY, Heinimann K, Albrecht C, D'Orazio D, Bendik I, et al: Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. Anticancer Res 2002; 22: 2215-2220.
13. Willoughby DA, Moore AR, Colville-Nash PR: COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355: 646-648.
14. Hawkey CJ: COX-2 inhibitors. Lancet 1999; 353: 307-314.